Orlando, Florida — October 16, 2025 — Leads & Copy — Vistagen (Nasdaq: VTGN) will present data on its investigational pherine nasal spray, PH80, at The Menopause Society 2025 Annual Meeting on Thursday, October 23, 2025.
PH80, a novel, non-systemic, non-hormonal, rapidly acting clinical stage pherine product candidate, is being evaluated as a potential treatment of vasomotor symptoms (hot flashes) due to menopause. The Company’s posters will discuss data from nonclinical and Phase 1 clinical studies of PH80.
Poster Presentations:
Date: Thursday, October 23, 2025, 6:15 p.m. to 7:15 p.m. Eastern Time
Title: PH80 Nasal Spray: In Vitro Receptor Binding, Effects on Reproductive Organs in Mice, and Pharmacokinetic Profile in Humans— A Potential, Novel, Rapid, Non-hormonal Treatment for Vasomotor Symptoms due to Menopause
Authors: Louis Monti, MD, PhD; Ross A. Baker, PhD; Rita Hanover, PhD
Poster Number: P-124
Date: Thursday, October 23, 2025, 6:15 p.m. to 7:15 p.m. Eastern Time
Title: PH80 Nasal Spray Effects on Brain and Autonomic Activity: A Potential, Novel, Rapid, Non-hormonal, Treatment for Vasomotor Symptoms due to Menopause
Authors: Louis Monti, MD, PhD; Ross A. Baker, PhD; Rita Hanover, PhD
Poster Number: P-13
Headquartered in South San Francisco, CA, Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines.
Vistagen is passionate about developing transformative treatment options to improve the lives of individuals underserved by the current standard of care for multiple highly prevalent indications, including social anxiety disorder, major depressive disorder, vasomotor symptoms (hot flashes) associated with menopause and premenstrual dysphoric disorder.
